Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
Burgess, B.T.; Anderson, A.M.; McCorkle, J.R.; Wu, J.; Ueland, F.R.; Kolesar, J.M. Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells. Diagnostics 2020, 10, 121. https://doi.org/10.3390/diagnostics10020121
Burgess BT, Anderson AM, McCorkle JR, Wu J, Ueland FR, Kolesar JM. Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells. Diagnostics. 2020; 10(2):121. https://doi.org/10.3390/diagnostics10020121
Chicago/Turabian StyleBurgess, Brian T.; Anderson, Abigail M.; McCorkle, J. R.; Wu, Jianrong; Ueland, Frederick R.; Kolesar, Jill M. 2020. "Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells" Diagnostics 10, no. 2: 121. https://doi.org/10.3390/diagnostics10020121